Germans Trias i Pujol Research Institute (IGTP)’s Post

#hiring Postdoctoral Scientist - Sasine Lab - Hematology & Cellular Therapy, Los Angeles, United States, fulltime #jobs #jobseekers #careers #LosAngelesjobs #Californiajobs #ScienceTechnology Apply: https://lnkd.in/gzt3BUQC Job Description Join us in groundbreaking research! The Sasine Laboratory is seeking a Postdoctoral Scientist to join our team! The Sasine Laboratory focuses on three important areas: The relationship between the bone marrow and multiple myeloma, a type of cancer. Delivery of macromolecules using extracellular vesicles. The interactions between chimeric antigen receptor

Join us for Challenge Workshop on the Non-Coding RNA Therapeutics, on June 23-27, 2024, for an in-depth exploration of the critical regulatory roles played by non-coding RNAs, including microRNAs, circRNAs, and lncRNAs, in various cellular processes.Their dysregulation in brain diseases presents new opportunities for targeted therapies. This Challenge Workshop is a great opportunity for scholars in RNA therapeutics and non-coding RNA function within the central nervous system to tackle key challenges facing RNA therapeutics in neuropsychiatric and neurodegenerative diseases, including non-coding RNA functionality, RNA drug chemistry, immune system recognition, and RNA delivery. Don't miss out - register now to secure your spot and be part of shaping the future of RNA therapeutics. More information: https://bit.ly/3xBfcgG Apply now: https://bit.ly/3U3SFke #Neuroscience #NonCodingRNATherapeutics #RNATherapeutics

Join InnoSer in raising awareness for #MultipleSclerosisAwarenessWeek ! 🧠 #MultipleSclerosis (MS) is the most common chronic inflammatory, demyelinating, and neurodegenerative disease. Together, we are working to cure MS, while spreading awareness of patients affected by MS. Currently, several disease-modifying treatments for MS are being investigated, example of which is #CART autologous cell therapy. 🔬 To help investigate the effectivness of new MS-specific therapies, InnoSer offers unique preclinical contract research services using in vivo MS models of de- and re-myelination. In the cuprizone model of MS, cuprizone induces oligodendrocyte death and reversible myelination, recapitulating the pathophysiology of MS. In the cuprizone rapamycin model, the addition of mTOR inhibitor, rapamycin, prevents spontaneous re-myelination by newly differentiated oligodendrocytes, thereby creating a more severe demyelinating phenotype. Both models, combined with InnoSer's highly sensitive behavioral readouts, represent highly relevant preclinical research tools to test efficacy of novel disease-modifying treatment for MS 💊. 👉 Learn more about how the cuprizone and cuprizone rapamycin models of MS can help you accelerate your preclinical research on InnoSer’s webpage: https://lnkd.in/emKxUyFF   #NeuroscienceCRO #EuropeanCRO #EuropeanNeuroscienceCRO

Exciting news! Our latest study in Cancers MDPI explores the genetic landscape of gastrointestinal stromal tumors (GISTs) in #Kuwait, focusing on KIT and PDGFRA mutations and clinical implications. #cancer #mdpi #oncology #genetics #precision #pharmacogenetics #ngs #molecular #cytology #histology #cytogenetics #immunohistochemistry

Drug targeting RNA modifications shows promise for treating neuroblastoma. Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive. Read: https://lnkd.in/eNzFuUgb #sciencesdelavie #biotechnology #biotechnology #innovation #innovations #research #sciences #medicaments #research #drugresearch #laboratories #labs #chemistry #chemistry #biology #biologie #biopharma #rna #rnatherapeutics #arn #revolution #happy

#PMC403 Angiopoietins (Angs) and their Tie receptors regulate lymphatic vessel development, and mutations of the ANGPT2 gene were recently found in human primary lymphedema. However, the mechanistic basis of Ang2 activity in lymphangiogenesis is not fully understood. Here, we used gene deletion, blocking Abs, transgene induction, and gene transfer to study how Ang2, its Tie2 receptor, and Tie1 regulate lymphatic vessels. We discovered that VEGF-C–induced Ang2 secretion from lymphatic endothelial cells (LECs) was involved in full Akt activation downstream of phosphoinositide 3 kinase (PI3K). Neonatal deletion of genes encoding the Tie receptors or Ang2 in LECs, or administration of an Ang2-blocking Ab decreased VEGFR3 presentation on LECs and inhibited lymphangiogenesis. A similar effect was observed in LECs upon deletion of the PI3K catalytic p110α subunit or with small-molecule inhibition of a constitutively active PI3K located downstream of Ang2. Deletion of Tie receptors or blockade of Ang2 decreased VEGF-C–induced lymphangiogenesis also in adult mice. Our results reveal an important crosstalk between the VEGF-C and Ang signaling pathways and suggest new avenues for therapeutic manipulation of lymphangiogenesis by targeting Ang2/Tie/PI3K signaling.

🧬 𝐓𝐫𝐚𝐧𝐬𝐟𝐞𝐫𝐫𝐢𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐢𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 🩺 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gsVyfirT The transferrin antibody market is experiencing growth due to the increasing demand for advanced diagnostic and research tools in the fields of immunology, oncology, and neuroscience. Transferrin is a glycoprotein responsible for iron transport in the blood, and antibodies against transferrin are used in various applications, including diagnostics, therapeutic research, and biomarker discovery. With the rising prevalence of chronic diseases such as cancer, anemia, and neurodegenerative disorders, there is a growing need for precise and targeted diagnostic solutions, driving demand for transferrin antibodies in both clinical and research settings. One of the primary drivers of the transferrin antibody market is its crucial role in research focused on iron metabolism and its impact on diseases. Iron homeostasis is critical for various biological processes, and its dysregulation is linked to conditions like anemia, hemochromatosis, and cancer. Transferrin antibodies are extensively used in laboratories to study the protein’s role in these disorders, contributing to the development of new therapies and diagnostic tests. Additionally, transferrin is increasingly being investigated as a potential biomarker for cancer and other diseases, further boosting the use of transferrin antibodies in research. #Company MyBioSource Bio-Techne abcam GeneTex, Inc. Biorbyt Arigo Biolaboratories Corp. LSBio | LifeSpan BioSciences, Inc. Assay Genie RayBiotech Abbexa OriGene Technologies, Inc. Creative Biolabs #Type • Monoclonal Antibody • Polyclonal Antibody #Application • Flow Cytometry • ELISA • Western Blot • Immunoprecipitation • Immunofluorescence • Other #TransferrinAntibody #Diagnostics #HealthcareInnovation #CancerResearch #Neuroscience #IronMetabolism #MonoclonalAntibodies #BiomedicalResearch #PrecisionMedicine #FutureOfHealthcare

Good opportunity

Postdoctoral Research Associate position is available in the tumor immunology lab of Sana Karam, MD, PhD, at Washington University, Radiation Oncology Postdoctoral Research Associate-Radiation Oncology Washington University School of Medicine See the full job description on jobRxiv: https://lnkd.in/dK3uhGFX #animal_husbandry #animal_models #biochemistry #bioinformatics #cancer_biology #cell_cultures #flow_cytometry #molecular_biology

🔉 We are thrilled to announce that the Consortium national de recherche sur les thérapies cellulaires et géniques (UNITC), WORKING GROUP ON TRAINING, INFORMATION, PATIENT ENGAGEMENT & INTEGRATION INTO THE EUROPEAN ECOSYSTEM is organizing the 1st UNITC MASTERCLASSES "Research in Cellular and Gene Therapies," offering 12 exclusive spots to work on and strengthen your research project. 🎓 APPLY NOW TO PARTICIPATE IN THE 2024 MASTERCLASSES 📅 Application deadline: September 20, 2024 Are you : 🎯 a physician, 🎯 pharmacist, 🎯 or qualified scientist, working in a hospital, cancer center, or research institution engaged in cellular and gene therapy research in oncology (solid and hematological tumors) and eager to: 🔺 Enhance your skills and expertise in all aspects of clinical, fundamental, and translational research (methodological, scientific, clinical, organizational, financial, collaborations...), 🔺 (Co)-develop research protocols in cellular and gene therapies, 🔺 And be mentored by leading experts in the field? 👇 Submit your application now! https://lnkd.in/dmvA-sBb The Consortium national de recherche sur les thérapies cellulaires et géniques (UNITC) is developed under the aegis of the FITC - Société Française d'Immuno-Thérapie du Cancer, the Institut Carnot CALYM, the Institut Carnot OPALE, the SFI Société Française d'Immunologie and the DESCAR-T French Registry. #CellularTherapy #GeneTherapy #CancerResearch #Oncology #MasterClass #ResearchOpportunity #ClinicalResearch #TranslationalMedicine #MedicalScience #Mentorship #UNITC #ResearchProtocols #CellAndGeneTherapy #CancerTreatment #ScientificCollaboration #MedicalInnovation